{
    "clinical_study": {
        "@rank": "134673", 
        "acronym": "COBALT", 
        "arm_group": [
            {
                "arm_group_label": "1:early conversion from Prograf\u00ae to Advagraf\u00ae", 
                "description": "patients converted from Prograf\u00ae to Advagraf\u00ae in the first 3 months after transplantation"
            }, 
            {
                "arm_group_label": "2:late conversion from Prograf\u00ae to Advagraf\u00ae", 
                "description": "patients converted from Prograf\u00ae to Advagraf\u00ae between 3 months and one year after transplantation"
            }
        ], 
        "brief_summary": {
            "textblock": "A study in which two groups of patients will be analysed; patients converted from Prograf to\n      Advagraf within the first 3 months after transplantation and patients converted from Prograf\n      to Advagraf between 3 months and 1 year after transplantation."
        }, 
        "brief_title": "A Multicenter Study in Liver Transplant Patients Converted From Prograf\u00ae to Advagraf\u00ae During the First Post-transplantation Year", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Transplantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with a liver transplant performed in the previous year and for whom the\n             conversion from Prograf\u00ae to Advagraf\u00ae was decided by the physician.\n\n        Exclusion Criteria:\n\n          -  Patient participating in an interventional clinical trial at the time of enrolment\n             into the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Liver transplant patients"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143479", 
            "org_study_id": "FR-Adv-NI-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1:early conversion from Prograf\u00ae to Advagraf\u00ae", 
                    "2:late conversion from Prograf\u00ae to Advagraf\u00ae"
                ], 
                "description": "oral", 
                "intervention_name": "Prograf", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK506", 
                    "tacrolimus"
                ]
            }, 
            {
                "arm_group_label": [
                    "1:early conversion from Prograf\u00ae to Advagraf\u00ae", 
                    "2:late conversion from Prograf\u00ae to Advagraf\u00ae"
                ], 
                "description": "oral", 
                "intervention_name": "Advagraf", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK506E", 
                    "tacrolimus"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pharmaco-epidemiology", 
            "Prograf", 
            "Tacrolimus", 
            "France", 
            "Observational"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "number_of_groups": "2", 
        "official_title": "A Cohort Study in Liver Transplant Patients Converted From a Tacrolimus Twice a Day (Prograf\u00ae) to Tacrolimus Once a Day (Advagraf\u00ae). French, Multisite, Observational Study", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Medical Dept Clinical Operations Dept", 
            "phone": "+ 31 (0)71 5455050"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma S.A.S.", 
            "last_name": "Medical and Scientific Affairs Manager, Transplantation", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of patients with a conversion ratio of tacrolimus dose of 1mg/1mg and percentage of patients with a ratio differing from 1mg/1mg", 
                "measure": "Conversion ratio of the daily dose of tacrolimus (mg Prograf\u00ae / mg Advagraf\u00ae)", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Number of days between the conversion date and the date of the first determination of C0 after conversion", 
                "measure": "Time of the first tacrolimus trough level (C0) after conversion", 
                "safety_issue": "No", 
                "time_frame": "From baseline to first determination of C0 (up to 6 months)"
            }, 
            {
                "description": "Percentage of patients with additional visit(s) and percentage of patients without an additional visit", 
                "measure": "Number of additional visits considered by the physicians to be due to the conversion (if required)", 
                "safety_issue": "No", 
                "time_frame": "At 6 months and at 1 year follow-up visit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of pills, number of treatment intake, treatment compliance, physician request, patient request, safety of treatment, center practice", 
                "measure": "Reasons for conversion", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Sociodemographic data, history of transplantation, comorbidities, complications after transplantation, risk factors, concomitant treatments (other than immunosuppressive protocols) and modification, if required, at 6 months and 1 year after conversion", 
                "measure": "Patient profile", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Date of initiation of treatment with Advagraf\u00ae\nTarget tacrolimus C0 (with Prograf\u00ae and with Advagraf\u00ae and recommendations for administration)\nDaily dose of Advagraf\u00ae\nAdjustments to Advagraf\u00ae dose since the previous visit: date, doses and reason for adjustment\nType and dose of immunosuppressive drugs combined with Advagraf\u00ae\nModification of the immunosuppressive regimen at 6 months and 1 year after conversion (if applicable) since the previous visit: date, modified treatment, type of modification, reason for modification\nImmunosuppressive regimen at the end of the visit at 6 months and 1 year after conversion, modified treatment, type of modification, reason for modification", 
                "measure": "Collection of immunosuppressive protocol details", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 6 months and 1 year follow-up visit"
            }, 
            {
                "measure": "Time to reach steady state", 
                "safety_issue": "No", 
                "time_frame": "From baseline to first determination of C0 (up to 6 months)"
            }, 
            {
                "description": "Ratio of daily dose of tacrolimus during achievement of steady state: mg Prograf\u00ae at conversion/mg Advagraf\u00ae during achievement of steady state. Percentage of patients with a ratio of 1mg/1mg and percentage of patients with a ratio differing from 1mg/1mg", 
                "measure": "Dose ratio at steady state", 
                "safety_issue": "No", 
                "time_frame": "From baseline and up to 6 months post-conversion"
            }, 
            {
                "measure": "The Intra -Patient Variability (IPV) of tacrolimus in patients on Prograf\u00ae and Advagraf \u00ae", 
                "safety_issue": "No", 
                "time_frame": "At baseline (Prograf) and during the 45 days after conversion (Advagraf)"
            }, 
            {
                "description": "Values and dates for renal parameters, liver parameters, blood glucose and Hepatitis C viral load", 
                "measure": "Latest available laboratory data with Prograf\u00ae before conversion and with Advagraf\u00ae", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 6 months and 1 year follow-up visit"
            }, 
            {
                "description": "Compliance with treatment at conversion (with Prograf\u00ae and only in group 2) and at 1 year after conversion (with Advagraf\u00ae for both groups) will be assessed using the Morisky questionnaire and a score will be calculated", 
                "measure": "Compliance with treatment at conversion", 
                "safety_issue": "No", 
                "time_frame": "At  baseline and at 1 year after conversion"
            }, 
            {
                "description": "Patients' quality of life at conversion (with Prograf\u00ae only in group 2) and at 1 year after conversion (with Advagraf\u00ae for both groups) will be assessed using the European Quality of Life-5 Dimensions 5 level (EQ5D-5L) questionnaire", 
                "measure": "Patients' quality of life at conversion", 
                "safety_issue": "No", 
                "time_frame": "At  baseline and at 1 year after conversion"
            }, 
            {
                "description": "Will be assessed on the basis of the number of acute rejections confirmed by biopsy and recorded adverse events and adverse reactions", 
                "measure": "Rate of acute rejection proven by biopsy (BPAR), graft survival rate and patient survival rate", 
                "safety_issue": "No", 
                "time_frame": "6 months and 1 year"
            }, 
            {
                "measure": "Occurrence of adverse events and/or effects", 
                "safety_issue": "No", 
                "time_frame": "From baseline until 1 year follow-up visit"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma S.A.S.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}